Company press releases
| Tid | Selskap | Tittel | Sektor | Kategori |
|---|---|---|---|---|
| 17 Oct 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’ | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 16 Oct 2023 08:51 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 09 Oct 2023 15:00 CEST |
LYTIX BIOPHARMA AS | Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 31 Aug 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma presents first half and second quarter 2023 results | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 28 Aug 2023 13:48 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial | 20103010 Biotechnology | Utsteders meldeplikt ved handel i egne aksjer |
| 24 Aug 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of second quarter 2023 results, August 31 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 11 Aug 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 03 Aug 2023 14:37 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the 2023 American Academy of Dermatology Association’s Innovation Academy meeting | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 20 Jul 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 21 Jun 2023 22:49 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: GRANT OF SHARE OPTIONS | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 25 May 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to present at ABG Sundal Collier Life Science Summit and Redeye Growth Day in Stockholm | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 11 May 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma presents first quarter 2023 results | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 04 May 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of first quarter 2023 results, Thursday 11 May | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 03 May 2023 07:55 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to present at the ‘Frontiers in Cancer Immunotherapy 2023’, invited by New York Academy of Sciences | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 19 Apr 2023 08:01 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma appoints new Chairman of the Board | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 18 Apr 2023 16:50 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: GRANT OF SHARE OPTIONS | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 18 Apr 2023 16:46 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma – Minutes of Ordinary General Meeting | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 11 Apr 2023 10:17 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Notice of Annual General Meeting on 18 April 2023 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 30 Mar 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Annual Report for 2022 | 20103010 Biotechnology | Årsrapporter og revisjonsberetninger |
| 16 Feb 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presents fourth quarter and second half 2022 results | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 09 Feb 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |